Advanced Hepatocellular Carcinoma (HCC) Clinical Trial
Official title:
A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib
This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at a continuous 150 mg twice daily (BID) dose.
Adult patients with advanced HCC previously treated with sorafenib will be randomized 2:1 to receive either single agent OSI-906 or placebo ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04985136 -
A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
|
Phase 3 | |
| Recruiting |
NCT02509169 -
Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04723004 -
Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
|
Phase 3 | |
| Completed |
NCT02814461 -
The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC
|
Phase 1 | |
| Not yet recruiting |
NCT04344158 -
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
|
Phase 3 | |
| Completed |
NCT02906397 -
Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)
|
Phase 1 | |
| Active, not recruiting |
NCT04523493 -
Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC
|
Phase 3 | |
| Terminated |
NCT05375604 -
A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)
|
Phase 1 | |
| Recruiting |
NCT05862181 -
The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma
|
||
| Not yet recruiting |
NCT06309485 -
Phase 2 Study of WGI-0301 in Combination With Sorafenib for Advanced HCC
|
Phase 2 | |
| Terminated |
NCT04212221 -
MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04605796 -
A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)
|
Phase 2 |